Browsed by
Tag: shares

GameStop, Microsoft partnership sends games retailer’s shares up 44%

GameStop, Microsoft partnership sends games retailer’s shares up 44%

  • GameStop shares rose 44% on Thursday after it announced a multiyear partnership with Microsoft.
  • GameStop will begin selling an “Xbox All Access” bundle stores, with an Xbox console and two-year digital subscription at no upfront cost.
  • It will roll out the use of Microsoft Dynamics 365, Teams, and Surface devices in its stores and offices, it said.
  • GameStop will also upgrade its e-commerce site as part of the partnership.
  • Visit Business Insider’s homepage for more stories.

GameStop on Thursday announced a multiyear partnership with Microsoft to upgrade its stores and offer a new Xbox console package for no up-front cost — sending its shares rocketing by 44%.

As part of the partnership, the world’s biggest video games retailer said it would offer buyers an “Xbox All Access” bundle, for zero upfront cost, that includes an Xbox console and a two-year digital subscription to Xbox Game Pass Ultimate, Microsoft’s “Netflix of gaming” subscription service.

Microsoft did not name a specific Xbox console that would be part of the bundle in a statement, but said that it was “excited about continuing and evolving [the] relationship for the launch of the Xbox Series” consoles, due November 10. 

GameStop will also upgrade its e-commerce site as part of the agreement.

It will integrate Microsoft’s cloud software and hardware into its stores to create what it calls the “ultimate gaming destination” for gamers. GameStop has more than 5,000 stores in 10 countries. It didn’t say how many of these stores would be upgraded.

GameStop will use Dynamics 365, Microsoft’s suite of cloud-based business applications, to standardize its back-end and in-store operations including finance, inventory, e-commerce, retail, and point of sale. 

Staff would be able to access insights spanning both e-commerce and in-store sales data, Microsoft said. This includes customer purchasing history, real-time data on product

Read the rest
2 cheap UK shares I’d buy today to get rich and retire early

2 cheap UK shares I’d buy today to get rich and retire early



a man and a woman walking down a dirt road


© Provided by The Motley Fool


The stock market crash has prompted some investors to avoid buying cheap UK shares. That’s understandable. They face challenging operating conditions at the present time in many cases. And that could lead to disappointing share price performances over the coming months.

However, long-term investors who can build a diverse portfolio of stocks could benefit from buying undervalued British shares after the recent market downturn. In time, they may produce sound recoveries that improve your financial prospects.

With that in mind, here are two FTSE 100 stocks that appear to be undervalued. They could be worth buying today, and may even boost your retirement prospects.

Loading...

Load Error

A buying opportunity among cheap UK shares

Glencore (LSE: GLEN) could offer good value for money relative to other cheap UK shares. The FTSE 100 mining business has experienced a tough period due to coronavirus. But its assets have largely been able to remain operational throughout the year.

In fact, its marketing division produced a record half-yearly profit that strengthened the company’s overall performance. It could remain a key differentiator for Glencore versus sector peers, since it offers counter-cyclical earnings potential.

Looking ahead, the company is forecast to return to positive earnings growth next year after a challenging 2020. This should aid it in seeking to reduce debt to more manageable levels. Meanwhile, its forward price-to-earnings (P/E) ratio of 12.5 suggests that investors may have factored in further disruption for the wider sector.

Clearly, a weak economic outlook is likely to cause investor sentiment towards commodity businesses to remain subdued in the short run. However, Glencore’s share price could offer recovery potential over the long run as part of a diverse portfolio of cheap UK shares.

A long-term recovery opportunity

Whitbread (LSE: WTB) is another FTSE 100 stock

Read the rest
Sri Lankan shares end higher on consumer, financial boost

Sri Lankan shares end higher on consumer, financial boost

Oct 8 (Reuters) – Sri Lankan shares marked their best session in nearly five months on Thursday, ending higher for a second straight session on the back of gains in consumer and financial stocks.

** The benchmark stock index ended up 3.09% at 5,724.54, its biggest intraday percentage gain since May 18.

** Commercial Leasing & Finance Plc and investment firm Carson Cumberbatch Plc were the top boosts to the index, gaining 27.8% and 9.6%, respectively.

** Finance company LOLC Development Finance Plc fell 3.6% and was the top drag on the index.

** Trading volume on the CSE All Share Index rose to 143.45 million, from 113.52 million a day earlier.

** Foreign investors were net sellers in the equity market, offloading 891.3 million Sri Lankan rupees ($4.84 million) worth of shares, according to exchange data.

** The Sri Lankan rupee was quoted at 184.15 against the U.S. dollar by 1240 GMT, 0.14% higher for the day compared with last session’s close of 184.4, according to Refinitiv data.

** Equity market turnover was 2.90 billion Sri Lankan rupees on Thursday, data showed.

** For a report on global markets, click

** For a report on major currencies, click ($1 = 184.1500 Sri Lankan rupees) (Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Aditya Soni)

Source Article Read the rest

Regeneron Shares Surge After Trump Praises COVID Treatment

Regeneron Shares Surge After Trump Praises COVID Treatment

Regeneron Pharmaceuticals  (REGN) – Get Report shares surged higher in pre-market trading Thursday after President Donald Trump praised its coronavirus antibody treatment and the drugmaker said it will seek emergency use authorization from the Food & Drug Administration. 

Regeneron said its REGN-COV2 treatment, a combination of two monoclonal antibodies, is designed to prevent the infectivity of SARS-CoV-2, the virus that causes COVID-19. The group has around 50,000 doses available for public use and said it would have doses available for “300,000 patients in total within the next few months” if the Emergency Use Authorization (EUA) is approved.

President Trump was injected with the treatment last week, according to his physicians, and he claimed in a video released late Wednesday to “feel good immediately” and suggested that “it just me me better. I call that a cure.” 

Regeneron shares were marked 4.6% higher in pre-market trading Thursday to indicate an opening bell price of $619.00 each, a move that would extend the stock’s six-month gain to around 20.8%.

Regeneron’s REGN-COV2, is undergoing a jointly run trial with the National Institute of Allergy and Infectious Diseases, of 2,000 people, as well as a separate study of 2,900 coronavirus patients who are in hospitals and ambulatory settings.

Earlier on Wednesday, Eli Lilly & Co. filed an EUA application with the FDA trial data showing that the experimental antibody, Y-CoV555, met both primary and secondary endpoints. 

The drugmaker had earlier noted that the treatment, which is being manufactured in a joint arrangement with Amgen Inc.  (AMGN) – Get Report. reduced the need for hospitalization and emergency-room visits among patients with moderate coronavirus symptoms.

Eli Lilly said it’s studying several neutralizing antibodes for the prevention and treatment of COVID-19, either in combination with other drugs or as a so-called monotherapy,

Read the rest
Dr. Audrey Kunin, M.D., Chief Creative Officer Of DERMAdoctor, Shares What It Takes For Your Brand To Have Staying Power During Difficult Times

Dr. Audrey Kunin, M.D., Chief Creative Officer Of DERMAdoctor, Shares What It Takes For Your Brand To Have Staying Power During Difficult Times

One of the major challenges facing small business owners and entrepreneurs heading into Q3 of this year was figuring out how to take action and move forward in the face of uncertainty. But as we enter Q4 in what has been an undeniably complex year, it pays to take notes from those founders who have weathered many storms over the life of their companies. I recently had the pleasure of speaking with Dr. Audrey Kunin, M.D., Founder and Chief Creative Officer of DERMAdoctor, on the factors that she believes have kept her award-winning brand relevant for over 20 years, and the key to staying on top when things seem like they’re ready to blow over.

Start By Doing What’s Rarely Done

As a young girl growing up in the 60’s with two generations of salesmen ahead of her, Dr. Kunin shared that it was her family’s encouragement that allowed her to hold onto her dreams of pursuing a medical career at a time when those thoughts were totally outside the norm. “They provided great support,” she said. “And no limitations to my dream.” 

After taking a dermatology rotation during her third year of medical school at the Medical College of Ohio, Dr. Kunin says she became entranced with the vast array of what the field had to offer. But as she became more experienced in her practice as a dermatologist, Dr. Kunin recognized the overall lack of accessibility when it came to personal care. Believing that the option to consult with a licensed dermatologist should be convenient, informative, and economical, Dr. Kunin launched DERMAdoctor at the end of 1998. Starting as an e-retailer back when the idea of websites and online shopping was just starting to catch on,

Read the rest